Patents by Inventor Mike Hannay

Mike Hannay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transdermal delivery system for the administration of rotigotine
    Patent number: 8617591
    Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: December 31, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
  • TRANSDERMAL DELIVERY SYSTEM FOR THE ADMINISTRATION OF ROTIGOTINE
    Publication number: 20120215185
    Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
    Type: Application
    Filed: April 27, 2012
    Publication date: August 23, 2012
    Applicant: UCB Pharma GmbH
    Inventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
  • Transdermal delivery system for the administration of rotigotine
    Patent number: 8246979
    Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: August 21, 2012
    Assignee: UCB Pharma GmbH
    Inventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
  • Transdermal delivery system
    Patent number: 8246980
    Abstract: An improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: August 21, 2012
    Assignee: UCB Pharma GmbH
    Inventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff
  • Transdermal delivery system for the administration of rotigotine
    Publication number: 20050079206
    Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer (1) wherein rotigotine in its free base form has been incorporated, (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix, (3) which is highly permeable for the free base of rotigotine, (4) which is impermeable for the protonated form of rotigotine, (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix. is provided. Said TDS provides for enhanced flux of rotigotine across the TDS/skin interface.
    Type: Application
    Filed: July 22, 2003
    Publication date: April 14, 2005
    Inventors: Dietrich Schacht, Mike Hannay, Hans-Michael Wolff
  • Transdermal delivery system
    Publication number: 20040081683
    Abstract: An improved Transdermal Delivery System (TDS) comprising a backing layer inert to the components of the matrix, a selfadhesive matrix containing an amine-functional drug and a protective foil or sheet to be removed prior to use, characterized in that
    Type: Application
    Filed: July 28, 2003
    Publication date: April 29, 2004
    Inventors: Dietrich Wilhelm Schacht, Mike Hannay, Hans-Michael Wolff